

## **S-Biomedic announces topline results of a successful clinical study in acne**

**S-Biomedic, a clinical-stage skin microbiome company pioneering the field of skin probiotics, today reports the successful completion of a phase 2 cosmetic study in acne-prone skin.**

Today S-Biomedic is announcing topline results of a successful double-blind placebo-controlled study for a first-of-its-kind LiveSkin Probiotics™ product for acne-prone skin. “This was one of the largest studies with the skin’s own bacteria that has ever been conducted. We were able to achieve our defined study goals without any problems” said Bernhard Paetzold, Chief Scientific Officer of S-Biomedic.

The tested active ingredient CutiModulis™ containing skin probiotic strains CA-31 and CA-81 showed an excellent performance across different parameters including statistically significant improvement in lesion count and redness reduction compared to vehicle. In line with our previous findings, we could also demonstrate a statistically significant change in the skin microbiome composition.

Wesley Carpentier, Chief Commercial Officer added: “This study is an important validation of our technology platform. Now, after 6 years of development, we have the first true LiveSkin Probiotics™ probiotic coming to the market, backed by extensive clinical and safety research.”

In February 2020, S-Biomedic and Royal DSM, a global, purpose-led company announced a collaboration and commercialization agreement with S-Biomedic to bring probiotic technology to the skincare market. The successful completion of this clinical study represents a key milestone of this collaboration.

Rishabh Pande, VP Marketing & Innovation, Personal Care at DSM commented: “The successful completion of this joint study marks an important milestone in our journey to bring this exciting technology to the market. We are very pleased with the positive results, which further reinforce the potential of this technology to have a positive impact on people’s lives.”

Within the next 36 months, S-Biomedic expects to be able to complete up to 9 marketable assets spanning both cosmetic and therapeutic dermatology applications in the field of acne care, healthy skin ageing and a number of undisclosed skin conditions.

### **About the product**

CutiModulis™ is our first-of-its-kind skin commensal probiotic product for acne-prone skin and contains a proprietary combination of two natural bacterial strains, namely CA-31® and CA-81®. Researchers at S-Biomedic specifically selected these strains that are native to the skin and have the potential to naturally thrive on the skin. Through this, they can modulate certain specific parameters of the physiology of our skin.

S-Biomedic is the first to demonstrate in a series of interventional clinical studies that carefully selected Cutibacterium strains (CA-31 and CA-81) are beneficial to the skin microbiome and can be used in mild to moderate acne.



### **About S-Biomedic**

S-Biomedic is at the forefront of harnessing the natural skin-microbiome to maintain skin health and address skin disease. S-Biomedic is a Belgium-based life-science company working with live skin commensal bacteria as well as bacterial fermentation products to develop treatments and products for skin care and skin disorders. S-Biomedic has developed technologies to directly modulate the skin microbiome, addressing unmet needs in dermatology as well as the cosmetic skincare industry. More information on [www.sbiomedic.com](http://www.sbiomedic.com).

### **About DSM**

Royal DSM is a global, purpose-led company in health, nutrition & bioscience, applying science to improve the health of people, animals and the planet. DSM's purpose is to create brighter lives for all. DSM's products and solutions address some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders – customers, employees, shareholders, and society at large. DSM and its associated companies employ approximately 23,000 people around the world and deliver annual net sales of about €10 billion. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at [www.dsm.com](http://www.dsm.com)